Patents by Inventor Deno Dialynas

Deno Dialynas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Homotrimeric extended OBG3 globular head and uses thereof
    Patent number: 7459433
    Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, homotrimer of OBG3 polypeptide fragment comprising globular domain and all or part of OBG3 collagen-like region, has been identified that has utility for reducing body mass, for maintaining weight loss, and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
    Type: Grant
    Filed: May 26, 2003
    Date of Patent: December 2, 2008
    Assignee: Serono Genetics Institute, S.A.
    Inventors: John Lucas, Jiunn-chern Yeh, Deno Dialynas
  • Agonists and antagonists of prolixin for the treatment of metabolic disorders
    Patent number: 7344843
    Abstract: The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of PROLIXIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.
    Type: Grant
    Filed: October 14, 2002
    Date of Patent: March 18, 2008
    Assignee: Serono Genetics Institute S.A.
    Inventors: John Lucas, Deno Dialynas, Kristen Briggs
  • Genobix agonists and antagonists for use in the treatment of metabolic disorders
    Publication number: 20070129291
    Abstract: The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of GENOBIX activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.
    Type: Application
    Filed: July 30, 2002
    Publication date: June 7, 2007
    Applicant: Genset S.A.
    Inventors: John Lucas, Deno Dialynas, Kristen Briggs
  • Gmg-2 polynucleotides and polypeptides and uses thereof
    Publication number: 20060293225
    Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, homotrimer of GMG-2 polypeptide fragment comprising globular domain and all or part of GMG-2 collagen-like region, has been identified that has utility for reducing body mass, for maintaining weight loss, and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
    Type: Application
    Filed: July 25, 2002
    Publication date: December 28, 2006
    Applicant: GENSET S.A.
    Inventors: Deno Dialynas, John Lucas, Aaron Scalia, Hiroaki Tanaka
  • Xcrf polynucleotides and polypeptides and uses thereof
    Publication number: 20060258567
    Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. XCRF polypeptides have been identified that are beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
    Type: Application
    Filed: March 26, 2003
    Publication date: November 16, 2006
    Applicant: SERONO GENETICS INSTITITE S.A.
    Inventors: Kristen Briggs, Deno Dialynas, John Lucas, Aaron Scalia
  • Homotrimeric extended obg3 globular head and uses thereof
    Publication number: 20060252678
    Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, homotrimer of OBG3 polypeptide fragment comprising globular domain and all or part of OBG3 collagen-like region, has been identified that has utility for reducing body mass, for maintaining weight loss, and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
    Type: Application
    Filed: May 26, 2003
    Publication date: November 9, 2006
    Applicant: Genset S.A.
    Inventors: John Lucas, Jiunn-chern Yeh, Deno Dialynas
  • OBG3 Fragments Inhibiting The Conversion Of Active OBG3 Into Less Active OBG3 And Other Compositions For Treatment Of Metabolic Disorders
    Publication number: 20050288223
    Abstract: The present invention relates to the field of obesity research. Fragments of OBG3 have been identified that reduce weight gain in animals. These fragments of OBG3 should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
    Type: Application
    Filed: May 7, 2003
    Publication date: December 29, 2005
    Applicant: Genset S.A.
    Inventors: John Lucas, Deno Dialynas
  • Gmg-3 gmg-4 and gmg-6 polynucleotides and polypeptides and uses thereof
    Publication number: 20050239696
    Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GMG-3, GMG-4, Cluster 1, GMG-6A, or GMG-6B polypeptides have been identified that are beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
    Type: Application
    Filed: January 15, 2002
    Publication date: October 27, 2005
    Applicant: Genset S.A.
    Inventors: Mary Erickson, Barbara Chicca, Bernard Bihain, Hiroaki Tanaka, Tom Chu, Deno Dialynas, Aaron Scalia
  • Agonists and antagonists of prolixin for the treatrment of metabolic disorders
    Publication number: 20050069971
    Abstract: The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of PROLIXIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.
    Type: Application
    Filed: October 14, 2002
    Publication date: March 31, 2005
    Applicant: Genset S.A.
    Inventors: John Lucas, Deno Dialynas, Kristen Briggs
  • Ngzipa,ngzipd,pgzipa and pgzipd polynucleotides and polypeptides and uses thereof
    Publication number: 20050065079
    Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. NGZIPA, NGZIPD, PGZIPA or PGZIPD polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
    Type: Application
    Filed: October 3, 2002
    Publication date: March 24, 2005
    Inventors: Aaron Scalia, Deno Dialynas, Kristen Briggs
  • Agonists and antagonists of moxifin for the treatment of metabolic disorders
    Publication number: 20050054565
    Abstract: The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of MOXIFIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.
    Type: Application
    Filed: July 29, 2002
    Publication date: March 10, 2005
    Inventors: John Lucas, Deno Dialynas, Kristen Briggs
  • Xobesin agonists and antagonists for the treatment of metabolic disorders
    Publication number: 20050003997
    Abstract: The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of XOBESIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.
    Type: Application
    Filed: July 31, 2002
    Publication date: January 6, 2005
    Inventors: John Lucas, Deno Dialynas, Kristen Briggs